Ikametin (Ibandronic Acid)

Ibandronic acid binds to hydroxyapatite on bone surfaces and is taken up by osteoclasts during bone remodeling. Inside the cells it blocks farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, leading to loss of essential prenylated proteins, osteoclast apoptosis, and reduced bone resorption.

The specific dose and dosing schedule of Ikametin are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and other individual factors. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety of ibandronic acid in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To order Ikametin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ikametin belongs to the bisphosphonate class, which directly inhibits osteoclast‑mediated bone resorption. Compared with calcium‑based supplements or selective estrogen receptor modulators, bisphosphonates like ibandronic acid provide a more potent reduction in fracture risk, especially for vertebral fractures, but share a similar safety profile that requires monitoring.

Ikametin should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and store them out of reach of children.

Ikametin is taken orally, usually as a tablet taken with a full glass of water on an empty stomach. Patients are advised to remain upright for at least 30 minutes after ingestion and to avoid food, beverages, or other medications that may interfere with absorption during that period.

Serious adverse events, although rare, include osteonecrosis of the jaw, atypical femoral fractures, and severe renal impairment. Patients should report persistent jaw pain, unusual thigh or groin pain, or sudden changes in kidney function to their healthcare provider promptly.

Ikametin is contraindicated in patients with severe renal impairment, known hypersensitivity to ibandronic acid or other bisphosphonates, and in individuals with esophageal abnormalities that delay emptying. It should also be avoided in patients who are pregnant or breastfeeding unless the prescriber determines that the benefits outweigh the risks.